Amna Nazir, Rizwan Ali, Muhammad Adil


Objective: To evaluate the efficacy of Bevacizumab in central serous chorioretinopathy (CSCR) Methodology: It is a randomized control trail. The study was conducted in Ophthalmology department of Allied Hospital, Faisalabad and Nishtar Hospital, Multan. From September 2016 to October 2017. Ethical approval was obtained from Hospital Ethics committee. Forty six patients took part in this study. Sample was collected using probability consecutive sampling technique. Computer software SPSS version 23 was used to analyze the data. Frequency and percentage was calculated for the qualitative variables like gender and Chi square test was applied to check the significance and association among variables. P value less than and equal to 0.05 was taken significant. Results: Forty six patients took part in the study belonging to both genders. There were 58.7% male (n=27) and 41.3% females (n=19) when gender distribution was analyzed. Mean and standard deviation for age came out to be 47.17±2.13. The baseline value for visual acuity had mean and standard deviation of 42.82±7.91, while Mean±S.D of visual acuity after treatment was 57.78±4.33. The difference between the means of visual acuity at baseline and after treatment was statistically significant (p=0.001). Similarly mean and standard deviation of central macular thickness before and after treatment was 357.89±96.17 and 149.76±30.19 µm respectively. There was reduction in the mean of central macular thickness after treatment and the difference between the two results was also statistically significant (p=0.001). Conclusion: This study concludes that bevacizumab is significantly effectual in the management of CSC. But more research work in the form of randomized controlled trails is required to evaluate the effectiveness of intravitreal bevacizumab in this condition.

Keywords: Bevacizumab, Chorioretinopathy, Visual acuity, Central macular.

Full Text: PDF
Download the IISTE publication guideline!

To list your conference here. Please contact the administrator of this platform.

Paper submission email:

ISSN 2422-8427

Please add our address "" into your email contact list.

This journal follows ISO 9001 management standard and licensed under a Creative Commons Attribution 3.0 License.

Copyright ©